Active, Not Recruiting
Safety Study of Abatacept to Treat Rheumatoid Arthritis (B) - IM101-045B
Updated:
17 January, 2019
|
ClinicalTrials.gov
Gender(s)
Age Range
Active, Not Recruiting
Inclusion Criteria: - Signed informed consent - Diagnosis of rheumatoid arthritis - > 18 years at index treatment initiation or switch - Starting treatment with abatacept or new disease-modifying anti-rheumatic drug (including switching or adding) or biologic disease modifying drug. - Read/write English Exclusion Criteria: - None
If you want to report a side effect, you can report directly to the Danish Medicines Agency via the website www.meldenbivirkning.dk
We recommend that you also contact BMS to report side effects.
Side effects and other reportable events are defined here
Report side effects or product quality complaints: Medical Information
466-DK-2200001